Vesicular stomatitis virus (VSV) is a promising oncolytic virus. Additionally, its glycoprotein G is the most commonly used envelope glycoprotein to pseudotype lentiviral vectors for gene therapy. However, G receptors (LDLR family members) are ubiquitous and expressed at the surface of non-target cells, precludingin vivogene therapy. Recently, we identified G mutants that no longer bind to LDLR but retain their fusion activity. This opened the possibility of specifically retargeting the glycoprotein to receptors of interest. Here, we constructed chimeric glycoproteins fused with a nanobody at the amino-terminus of G. By experimental evolution, we identified two mutations in G improving the folding and functionality of chimeric Gs, regardless of the nanobody inserted at the amino-terminus. We then constructed chimeric glycoproteins using several nanobodies targeting HER2 receptor and, into these chimeras, we introduced mutations that abolish the recognition of LDL receptors. VSV and lentiviruses pseudotyped with these glycoproteins specifically infect cells expressing HER2. We have therefore identified G mutations that optimize the G scaffold to tolerate amino-terminal insertion of a nanobody and establish proof of concept that this approach can be used to confer a new tropism on G. This paves the way for targetedin vivotherapies.